Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Theragenics, Juniper Investment Company LLC deal

Theragenics said investment firm Juniper will acquire the 93% of the biotech it does not already own for $2.20 per share in cash, or about $63.9 million based on 31.2 million shares outstanding on Aug. 2. The offer is a 48% premium to Theragenics' close of $1.49 on May 10, before the proposal was announced,

Read the full 558 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers